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Abstract
Background: To show magnetic resonance imaging (MRI) texture appearance change in non-
Hodgkin lymphoma (NHL) during treatment with response controlled by quantitative volume
analysis.
Methods: A total of 19 patients having NHL with an evaluable lymphoma lesion were scanned at
three imaging timepoints with 1.5T device during clinical treatment evaluation. Texture
characteristics of images were analyzed and classified with MaZda application and statistical tests.
Results: NHL tissue MRI texture imaged before treatment and under chemotherapy was classified
within several subgroups, showing best discrimination with 96% correct classification in non-linear
discriminant analysis of T2-weighted images.
Texture parameters of MRI data were successfully tested with statistical tests to assess the impact
of the separability of the parameters in evaluating chemotherapy response in lymphoma tissue.
Conclusion: Texture characteristics of MRI data were classified successfully; this proved texture
analysis to be potential quantitative means of representing lymphoma tissue changes during
chemotherapy response monitoring.
Background
Quantitative image analysis may provide new clinically
relevant information on the target of interest, constituting
a major advantage in clinical work as well as in research.
The most significant objectives in quantitative image anal-
ysis are to find tissue-characterizing features with biologi-
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cal significance and which correlate with pathophysiology
detected by other methods, i.e. clinical examination, other
imaging modalities and pathological-anatomical diagno-
sis, and secondly to provide this new information on the
properties of tissues to be used alone or in combination
with other clinical information allowing more reliable
detection of disease and sophisticated tissue classification
as a clinical diagnostic and follow-up tool.
Precise and earlier diagnostics and monitoring treatment
response are significant both for the individual patient's
prognosis and on a larger scale in developing treatment
procedures, especially in malignant diseases. Within the
research on solid tumors extensive and widely used
Response Evaluation Criteria in Solid Tumors (RECIST)
Guidelines may be followed to obtain intra- and inter
center comparable results. RECIST defines measurability
of tumor lesions and specifies methods of measurements
with different techniques [1]. According to the RECIST cri-
teria measure of tumor response from radiological images
is done by measuring lesions one-dimensionally, further-
more the World Health Organization (WHO) criteria use
two dimensional analysis and several research groups vol-
umetric three-dimensional analysis [2].
Staging of non-Hodgkin's lymphomas (NHL) is the key
element of treatment planning for this heterogeneous
group of malignancies. A variety of diagnostic tools,
including biopsies, computed tomography (CT), mag-
netic resonance imaging (MRI), 18F-fluorodeoxyglucose
positron emission tomography (FDG-PET) or molecular
markers are used in pre-treatment staging [3]. Enhance-
ment with contrast media could also help the evaluation
in using different imaging modalities. The same tools are
applied to evaluate the response to different types of treat-
ment. Novel techniques such as hybrid positron emission
tomography – computed tomography (PET-CT) imaging
and new PET tracers like 18F-fluoro-thymidine (18F-FLT)
may increase the sensitivity of response assessment [4].
Reports aiming international standardization of clinical
response criteria for NHL have been published [5,6], and
these criteria are in wide clinical use. A combination of
cyclophosphamide, doxorubicin, vincristine and pred-
nisone (CHOP) remains the mainstay of therapy. The
addition of a chimeric-anti-CD20 immunoglobulin G1
monoclonal antibody, rituximab (Mabthera®), has
resulted in a dramatic improvement in the outcome of the
most common NHL, diffuse large B-cell lymphoma, but
has also been shown to effective in other type of B-cell
lymphomas [7-9].
Several quantitative MRI studies have indicated that tex-
ture analysis (TA) has the ability to detect differences
between tissues and subtle changes between disease bur-
den and normal tissue. Successful applications of TA have
been reported from studying neurological diseases [10-
15], brain tumors [16,17], amygdale activation [18], mus-
cles [19,20], trabecular bone [21-23], liver [24-26], breast
cancer [27-31] and lymphomas [32].
In this paper we report the ability of TA to detect changes
in NHL solid tissue masses during chemotherapy. The
change in texture appearance is controlled by quantitative
volumetric analysis. We classify statistical, autoregressive
(AR-) model and wavelet texture parameters representing
pre-treatment and two under chemotherapy stages of
tumors with four analyses: raw data analysis (RDA), prin-
cipal component analysis (PCA), linear (LDA) and non-
linear discriminant analysis (NDA). The final objective is
to show that these texture parameters of MRI data can be
successfully tested with Wilcoxon paired test and Repeat-
ability and Reproducibility (R&R) test for assess the
impact of the parameters usability in evaluating chemo-
therapy response in lymphoma tissue.
Methods
Tumor Response Evaluation (TRE) is a wide prospective
clinical project ongoing at our university hospital on can-
cer patients, where tumor response to treatment is evalu-
ated and followed up using simultaneously CT, MRI and
PET imaging methods. Clinical responses for these lym-
phoma patients were assessed according to the guidelines
of the international working group response criteria. In
this texture analysis study, as a part of extensive project,
the focus was on quantitative imaging methods and only
the response in predefined solid NHL masses was evalu-
ated. The ethics committee of the hospital approved the
study and participants provided written informed con-
sent. Primary inclusion criteria were NHL patients with at
least one bulky lesion (over 3 centimeters) coming for cur-
ative aimed treatment. Exclusion criteria were central
nervous disease, congestive heart failure New York Heart
Association Classification (NYHA) III-IV, serious psychi-
atric disease, HIV infection and pregnancy.
Patients
MRI images of nineteen NHL patients participating in the
TRE project were selected for the first part of this study.
One of these patients was excluded due to the smaller
amount of image data from the second part analyses.
There were 14 male and 5 female patients aged 34–75.
These patients had untreated or relapsed histologically
diagnosed high/intermediate (N = 8, 42%) or low-grade
(N = 11, 58%) NHL with an evaluable lymphoma lesion
either in the abdominal area (N = 16) or in the clavicular
and axillary lymph node area (N = 3). The treatment given
was chemotherapy alone or combined with humanized
antibody, rituximab (Mabthera®). Therapy regimens were
CHOP (N = 5), R-CHOP (rituximab and CHOP) (N = 8),
and CVP (cyclophosphamide, vincristine and pred-Journal of Experimental & Clinical Cancer Research 2009, 28:87 http://www.jeccr.com/content/28/1/87
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nisone) (N = 1), CHOP-like CNOP (cyclophosphamide,
mitoxantrone, vincristine and prednisone) (N = 1), ChlP
(chlorambucil and prednisone) (N = 1), starting with
CHOP and changing to R-CHOP (N = 2), starting with R-
CHOP and changing to R-CVP (N = 1). Chemotherapy
regimens were selected according to patients' clinical sta-
tus. Chemotherapy courses were repeated every three
weeks, and 4 to 9 courses were given according to clinical
response. Two patients received 4 cycles, four patients 6
cycles, one patient 7 cycles, and 11 received 8 cycles, and
one 9 cycles.
MR imaging schedule
MR imaging in clinical practice as well as in this study was
carried out at staging phase before any treatment (exami-
nation 1, E1), after the first chemotherapy cycle (examina-
tion 2, E2), and after the fourth chemotherapy cycle
(examination 3, E3). In addition patients were followed
up by using MRI six months and 6–61 months after the
completion of therapy. The time frame of the study is pre-
sented in Figure 1.
MR image acquisition
Imaging was performed on a 1.5 T MRI device (GE Signa,
Wisconsin, USA).
One contrast enhanced sequence acquired from the first
and second imaging timepoint were included for volume
analysis of lymphoma masses. The sequence used was
axial T2-weighted fast spin echo (FSE) fat saturation (FAT
SAT) sequence (TR 620 ms, TE 10 ms), with intravenous
contrast agent gadolinium chelate (gadobenate dimeglu-
mine, 0.2 mg/ml, 10 ml), slice thickness ranged from 5
mm to 12 mm.
One or two T1- and T2-weighted axial image serquences
from the first three imaging timepoints of every patient
were taken for texture analysis. The T1-weighted series
comprised T1-weighted spin echo (SE) and T1-weighted
SE FAT SAT sequences (TR 320–700 ms, TE 10 ms), the
T2-weighted sequences were FSE FAT SAT (TR 3 320–10
909 ms, TE 96 ms). Repetition time TR varied between
and within patients. Slice thickness varied between
patients according to clinical status from 5 mm to 12 mm;
most patients had two different slice thickness series, the
general combination was 5 mm and 8 mm series. Pixel
size varied from 1.33 mm*1.33 mm to 1.80 mm*1.80
mm, and a 256*256 matrix was used.
Texture analysis with MaZda
Texture parameter calculation was the first stage of the tex-
ture analyses. Stand-alone DICOM viewer application was
used to select three to five slices from every image series
for analysis. Region of interest (ROI) setting and texture
analysis were carried out with MaZda software (MaZda
3.20, The Technical University of Lodz, Institute of Elec-
tronics) [33,34]. The lymphoma masses were manually
selected and set as ROIs (Figure 2). Texture features calcu-
lated were based on histogram, gradient, run-length
matrix, co-occurrence matrix, autoregressive model and
wavelet-derived parameters [34]. Image grey level inten-
sity normalization computation separately for each ROI
was performed with method limiting image intensities in
the range [μ-3σ, μ+3σ], where μ is the mean grey level
value and σ the standard deviation. This method has been
shown to enhance differences between two classes when
comparing image intensity normalization methods in tex-
ture classification [35].
Fisher coefficient (Fisher) and classification error proba-
bility (POE) combined with average correlation coeffi-
cients (ACC) provided by MaZda were used to identify the
most significant texture features to discriminate and clas-
sify the three evaluation stages of lymphoma tissue. Ten
texture features were chosen by both methods (Fisher,
POE+ACC). This feature selection was performed sepa-
rately for the T1- and T2-weighted image sets. In these
subgroups feature selection was run for the following
imaging stages: combination of all imaging timepoints
(E1, E2, and E3), and all combinations of the two afore-
mentioned. Slice thickness was not taken into account.
Volumetric analysis
The volumetry of the solid lymphoma masses was evalu-
ated between diagnostic stage (E1) and after the first treat-
ment (E2). The masses were selected for evaluation before
chemotherapy. The same masses were followed after the
Time frame of the study Figure 1
Time frame of the study. E1-E5 refers to the MRI exami-
nation timepoints 1–5, respectively.Journal of Experimental & Clinical Cancer Research 2009, 28:87 http://www.jeccr.com/content/28/1/87
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first treatment. Volumetric analysis based on MRI images
was performed with semiautomatic segmentation soft-
ware Anatomatic™ [36] with region growing method.
[37].
Clinical parameters analyses
The patients' subjective views on their clinical symptoms
was observed between two stages: at the diagnosis and
after the first treatment. The subjective views were set in
two groups: symptoms unchanged or relieved.
Grade of malignity was classed into two groups: 1) low; 2)
high/intermediate.
Tissue classification
B11 application (version 3.4) of MaZda software package
was used for texture data analysis and classification. Anal-
yses were run between all combinations of imaging stages
separately for T1- and T2-weighted images. Analyses were
performed for combination of parameters selected auto-
matically with Fisher and POE+ACC methods for 1) the
specific imaging timepoint pair in question and 2) for all
imaging stages in particular image type (T1-, T2-
weighted). Feature standardization was used in B11, the
mean value being subtracted from each feature and the
result divided by the standard deviation. Raw data analy-
sis (RDA), principal component analysis (PCA), and lin-
ear (LDA) and nonlinear discriminant analysis (NDA)
were run for each subset of images and chosen texture fea-
ture groups. B11 default neural network parameters were
used. Nearest-neighbor (1-NN) classification was per-
formed for the raw data, the most expressive features
resulting from PCA and the most discriminating features
resulting from LDA. Nonlinear discriminant analysis car-
ried out the classification of the features by artificial neu-
ral network (ANN). These classification procedures were
run by B11 automatically.
Statistical analyses
Statistical analyses were run for the texture features
MaZda's automatic methods (Fisher and POE+ACC) had
shown to give best discrimination between imaging time-
points. The T1- and T2-weighted image texture parameters
were tested separately. Texture parameters for 18 patients
were included in the test, one patient participating in
MaZda texture parameter calculation was excluded
because of smaller amount of image data than other
patients leading to reduced textural data.
In analyzing and seeking the best parameters for classifi-
cation, it is vital to ensure low overall variation in the
treatment process and to ascertain how this variation can
be focused onto different components in the whole proc-
ess. In the present study the repeatability and reproduci-
bility (R&R) method was applied. The design of the study
was experimental, the aim being to estimate different
sources of variation in the lymphoma texture at the three
different timepoints (examinations 1, 2, and 3) and
Axial T1-weighted fat saturation image slice of the abdomen of a typical subject (left), and ROI drawn on lymphoma mass  (right) Figure 2
Axial T1-weighted fat saturation image slice of the abdomen of a typical subject (left), and ROI drawn on lym-
phoma mass (right).Journal of Experimental & Clinical Cancer Research 2009, 28:87 http://www.jeccr.com/content/28/1/87
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repeating the same measurements three times. Because
the distributions were skewed, the range method was
used.
According to the standard Gage R&R terminology time-
points stand for operators, patients for parts and repeated
measurements for trials. In statistical terms the following
variance components were estimated: repeatability (dif-
ference across measurements), reproducibility (difference
across timepoints) and variability (difference across
patients). Repeatability describes intrapatient variation,
i.e., how a given measurer repeats the same planning proc-
ess. Reproducibility describes interpatient variation, i.e.,
how different measurements at the timepoints follow the
same planning process and variability describes interpa-
tient variation, i.e. how well the same physician can repeat
the planning process for different kinds of patients. The
total error – also known as the combined R&R effect –
includes repeatability and reproducibility, and only
patient-to-patient variation is excluded. In industrial
applications the combined R&R should not exceed 10%
of the total variation, but in certain situations a total error
up to 30% may be acceptable. The present statistical anal-
yses were performed by Statistica/W (Version 5.1, 98 edi-
tion, Statsoft. Inc, Tulsa, OK, USA).
Textural data from T1- and T2-weighted fat saturation
image series were analysed separately and both groups
divided into two subgroups according to slice thickness:
5–7 mm and 8–12 mm. Differences between imaging
timepoints were analysed by Wilcoxon Signed Ranks.
Mann-Whitney test was used to test rank parameters
grouped by grade of malignity and subjective change of
symptoms. These analyses were performed by SPSS for
Windows, version 14.0.2.
Results
Volumetric analysis
The median volume of the lymphoma masses before treat-
ment (E1) was 429 cm3, ranging from 72 cm3 to 2144
cm3. The median volume of the masses calculated from
the second imaging timepoint (E2) was 190 cm3, ranging
from 30 cm3 to1622 cm3. After the first treatment cycle,
the lymphoma mass volume had decreased in all patients.
The median decline in volume was 32%, ranging from 3%
to 76%. The results of this volumetric analysis have been
published earlier in more detail [37]. The volumetry
results of the first and second imaging are given in cm3,
and the volume change is calculated in percentages in
Table 1.
Clinical parameters analyses
According to the patient's subjective estimates clinical
symptoms between first and second imaging timepoint
were unchanged in eight patients and relieved in 11
patients. Grades of malignancy and subjective view on
symptoms are presented in Table 1 with volumetry results.
Table 1: Grade of malignancy (1 = low, 2 = high/intermediate), subjective view of change in symptoms between pretreatment stage 
(E1) and after first chemotherapy cycle (E2) (0 = unchanged, 1 = relieved).
Patient Grade of malignity Symptoms Volume
1 = low
2 = high/intermediate
0 = unchanged
1 = relieved
E1 (cm3) E2 (cm3) Change%
1 2 1 429 105 -76%
2 2 1 183 64 -65%
3 1 1 173 66 -62%
4 1 1 529 459 -13%
5 1 0 570 419 -26%
6 1 1 800 595 -26%
7 2 1 146 118 -19%
8 2 0 118 80 -32%
9 1 1 367 246 -33%
10 1 0 850 769 -10%
11 2 1 2144 1622 -24%
12 2 1 72 30 -58%
13 2 0 140 52 -63%
14 2 1 274 93 -66%
15 1 1 795 190 -76%
16 1 0 824 797 -3%
17 1 0 750 579 -23%
18 1 0 273 66 -76%
19 1 0 771 522 -32%
Results of the volumetric analysis of first (E1) and second imaging stages (E2). Volumes are given in cm3, and the volume change calculated in 
percentages.Journal of Experimental & Clinical Cancer Research 2009, 28:87 http://www.jeccr.com/content/28/1/87
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Texture data: MaZda and B11 analyses
We included in the analyses 108 T1-weighted and 113 T2-
weighted images from E1; 103 T1-weighted and 105 T2-
weighted images from E2; and 97 T1-weighted images and
99 T2-weighted images from E3.
Texture features were selected with Fisher and POE+ACC
methods in MaZda from 300 original parameters calcu-
lated for each of the four subgroups in both image data
classes T1- and T2-weighted.
We found that the most significant features varied clearly
between imaging stages. The whole of 74 TA features
ranked first to tenth significant feature in tested sub-
groups. There were three histogram parameters, 55 co-
occurrence parameters, nine run-length parameters, four
absolute gradient parameters and three autoregressive
model parameters. No wavelet parameters were placed in
the top group.
Data analyses RDA, PCA, LDA and NDA show texture
changes between imaging points. The analyses did not
perform well the task of discriminating all three imaging
timepoints (E1, E2, E3) at same time. Slightly better clas-
sification was achieved between the first and second
examinations, and between the second and third exami-
nations. The method was successful in classifying the tex-
tural data achieved from the pre-treatment and third
imaging timepoints, the best discrimination was obtained
within T2-weighted leading to NDA classification error of
4%, and within T1-weighted NDA 5% error. Classification
of different examination stages lead to same level results
in T1- and T2-weighted images. The overall classification
results are presented in Table 2 and Table 3.
Texture data: Statistical analyses
The values of 73 features obtained with MaZda feature
selection methods were tested with Wilcoxon paired test
for groups obtained from imaging timepoints a) E1 and
E2, b) E2 and E3, c) E1 and E3. T1- and T2-weighted fat
saturation image series data were set as their own groups
and further into two subgroups according to slice thick-
ness: 5–7 mm and 8–12 mm.
R&R test parameter repeatability was used to describe the
variation in texture features between image slices within
imaging sequence, and parameter reproducibility to
describe the variation between examination stages. This
test was performed separately for T1- and T2-weighted
images in all three combinations of two imaging points.
Differences in slice thickness were not taken into account.
Reproducibility values were expected to be quite large
because the aim was that the treatment given between
imaging stages would take effect and be shown in image
texture. In contrast, repeatability values (i.e. differences
between images taken at the same timepoint) were
expected to be zero. There is no exact expected ratio for
reproducibility and patient-to-patient variation in such
studies and thus no exact value for percentage of repro-
ducibility, so that the difference between different imag-
ing stages was significant.
The texture parameters giving the best discrimination
within T1-weighted image groups in two imaging stage
comparison are given in Table 4, Table 5 and Table 6; and
respectively for T2-weighted image groups in Table 7,
Table 8 and Table 9. Reproducibility percentage and
Repeatability percentage of the total are given for all
parameters. Wilcoxon paired test p-values are given for all
parameters for separate groups regarding slice thickness
(groups 5–7 mm and 8–12 mm).
Table 2: MaZda classification results – results obtained within T1-weighted images.
T1-weighted images classification RDA PCA LDA NDA
Examinations mis% mis% mis% mis%
E1, E2, E3 Combination E1, E2, E3 36% 34% 46% 31%
E1, E2 Combination E1, E2, E3 36% 34% 46% 31%
Combination E1, E2 24% 26% 34% 16%
E1, E3 Combination E1, E2, E3 18% 18% 13% 6%
Combination E1, E3 17% 17% 15% 5%
E2, E3 Combination E1, E2, E3 26% 26% 34% 18%
Combination E2, E3 25% 27% 30% 13%
Imaging timepoint (E1, E2, E3) combinations for classification analyses. Feature selection methods given in rows. Misclassification percentage (mis%) 
given for raw data analysis (RDA), principal component analysis (PCA), linear discriminant analysis (LDA) and non-linear discriminant analysis 
(NDA) in columns. "Combination E1, E2, E3" in feature selection methods refers to features, which have proved to give best discrimination in all 
imaging timepoints analyses with Fisher and POE+ACC methods, combination of two imaging timepoints refers respectively to features from the 
analyses in question.Journal of Experimental & Clinical Cancer Research 2009, 28:87 http://www.jeccr.com/content/28/1/87
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Table 3: MaZda classification results – results in groups of T2-weighted images.
T2-weighted images classification RDA PCA LDA NDA
Examinations Feature selection method mis% mis% mis% mis%
E1, E2, E3 Combination E1, E2, E3 34% 35% 47% 30%
E1, E2 Combination E1, E2, E3 29% 29% 39% 19%
Combination E1, E2 37% 35% 40% 35%
E1, E3 Combination E1, E2, E3 15% 14% 19% 4%
Combination E1, E3 16% 17% 21% 4%
E2, E3 Combination E1, E2, E3 25% 24% 25% 14%
Combination E2, E3 24% 23% 30% 12%
Imaging timepoint (E1, E2, E3) combinations for classification analyses. Feature selection methods given in rows. Misclassification percentage (mis%) 
given for raw data analysis (RDA), principal component analysis (PCA), linear discriminant analysis (LDA) and non-linear discriminant analysis 
(NDA) in columns. "Combination E1, E2, E3" in feature selection methods refers to features, which have proved to give best discrimination in all 
imaging timepoints analyses with Fisher and POE+ACC methods, combination of two imaging timepoints refers respectively to features from the 
analyses in question.
Table 4: Summary table of texture parameters ranked 1-10 with Fisher and POE+ACC methods according to test subgroup T1-
weighted images and imaging timepoints E1 and E2.
T1-WEIGHTED IMAGES R&R R&R Wilcoxon Wilcoxon
E1-E2 analyses Repeatability % of total Reproducibility % of total Slice thickness <8 mm
p
Slice thickness >= 8 mm
p
HISTOGRAM PARAMETERS
Percentile, 1% 15.349 0.069 0.286 0.672
CO-OCCURENCE MATRIX 
PARAMETERS
Difference entropy S(1,0) 6.874 25.411 0.074 0.018
Difference entropy S(0,1) 7.725 26.783 0.074 0.028
Difference entropy S(1,1) 6.970 24.413 0.139 0.018
Difference entropy S(2,0) 8.409 28.186 0.114 0.018
Sum average S(0,2) 52.143 4.597 0.285 0.499
Difference entropy S(2,2) 11.265 22.824 0.093 0.018
Difference entropy S(3,0) 15.434 11.836 0.241 0.018
Angular second moment S(5,-5) 18.976 7.234 0.093 0.612
Sum of squares S(5,-5) 58.267 1.780 0.721 0.310
Sum average S(5,-5) 15.420 16.235 0.445 1.000
RUN-LENGTH MATRIX 
PARAMETERS
Grey level nonuniformity, 0° 6.015 43.441 0.051 0.128
Grey level nonuniformity, 90° 8.822 35.055 0.028 0.091
Grey level nonuniformity, 45° 4.635 13.324 0.028 0.176
Grey level nonuniformity, 135° 4.734 39.630 0.037 0.249
ABSOLUTE GRADIENT 
PARAMETERS
Variance 28.133 22.699 0.445 0.018
AUTOREGRESSIVE MODEL 
PARAMETERS
Teta 2 65.193 2.741 0.575 0.237
Teta 4 66.319 2.285 0.575 0.398
Texture parameters are given in rows. In the columns R&R repeatability and reproducibility of total, and Wilcoxon test for fat saturation series 
grouped with image slice thickness less than 8 mm, and 8 mm or thicker.Journal of Experimental & Clinical Cancer Research 2009, 28:87 http://www.jeccr.com/content/28/1/87
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R&R inverted ratio and the small difference between val-
ues are associated with poor results in Wilcoxon test with
certain exceptions. Comparisons between first and third
imaging points achieved significant Wilcoxon test p-val-
ues most consistently: within T2-weighted images in both
slice thickness groups, and within T1-weighted images in
the group of thinner slices. Features ranked in T1-
weighted image data were tested in T2-weighted image
data and vice versa. These tests with ranked features trans-
posed with T1- and T2-weighted image groups lead to sta-
tistically relevant p-values in thinner T1-weighted images
and all images in T2-weighted group. In the analyses of
first and second imaging timepoints thin slices in general
achieved poorer separation than thick slices. Between the
second and third imaging sessions Wilcoxon test gave an
unsatisfactory result in T1-weighted group. This trend can
be seen in the B11 classification results in the framework
of T1-weighted images, while the T2-weighted image anal-
yses in B11 show better classification between second and
third than first and second imaging points. The best over-
all discrimination between imaging timepoints in T1-
weighted images was given by the run-length matrix
parameters describing grey level non-uniformity, run-
length non-uniformity, short-run emphasis and fraction
of image in runs in one or more directions calculated
(horizontal, vertical, 45 degrees and 135 degrees). In the
framework of T2-weighted image analyses best the per-
formers were absolute gradient mean and grey level non-
uniformity There were some scattering in well acquitted
parameters between sub analyses.
Mann-Whitney test was performed for all texture features
ranked 1–5 in any classification sub-analysis separately in
T1- and T2-weighted images and further subgroups
according to slice thickness to analyze differences between
stage of malignity (low vs. high/intermediate) and
between subjective change of symptoms (unchanged vs.
relieved). These analyses did not yield any relevant and
consequential additional information on the relation of
texture features to grouping parameters.
Table 5: Summary table of texture parameters ranked 1-10 with Fisher and POE+ACC methods according to test subgroup T1-
weighted images and imaging timepoints E2 and E3.
T1-WEIGHTED IMAGES R&R R&R Wilcoxon Wilcoxon
E2-E3 analyses Repeatability % of total Reproducibility % of total Slice thickness <8 mm
p
Slice thickness >= 8 mm
p
HISTOGRAM PARAMETERS
Variance 11.452 22.145 0.953 0.465
CO-OCCURENCE MATRIX 
PARAMETERS
Contrast S(2,0) 31.815 28.807 0.139 0.465
Contrast S(3,0) 27.957 40.317 0.051 0.144
Difference variance S(3,0) 26.169 35.250 0.139 0.273
Contrast S(4,0) 29.032 37.330 0.051 0.144
Correlat S(4,0) 25.661 36.025 0.086 0.144
Correlat S(0,4) 21.528 38.249 0.139 0.068
Correlat S(5,0) 23.130 39.697 0.038 0.068
Sum average S(5,0) 55.837 4.961 0.214 0.144
Sum average S(0,5) 44.169 6.142 0.859 0.715
Inverse difference moment S(5,5) 53.397 24.684 0.678 0.465
Difference variance S(5,-5) 50.986 14.473 0.515 0.715
RUN-LENGTH MATRIX 
PARAMETERS
Grey level nonuniformity, 0° 6.015 43.441 0.066 0.273
Run length nonuniformity, 45° 7.013 31.416 0.139 0.068
Grey level nonuniformity, 45° 4.635 13.324 0.066 0.465
Short run emphasis, 135° 13.062 21.630 0.021 0.144
ABSOLUTE GRADIENT 
PARAMETERS
Mean 24.582 28.201 0.038 0.144
Kurtosis 60.387 1.194 0.767 1.000
AUTOREGRESSIVE MODEL 
PARAMETERS
Teta 3 58.511 0.000 0.028 0.465
Texture parameters are given in rows. In the columns R&R repeatability and reproducibility of total, and Wilcoxon test for fat saturation series 
grouped with image slice thickness less than 8 mm, and 8 mm or thicker.Journal of Experimental & Clinical Cancer Research 2009, 28:87 http://www.jeccr.com/content/28/1/87
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Discussion
The goals of this study were show that a) MRI texture anal-
ysis can be used in NHL chemotherapy response evalua-
tion b) statistical tests Wilcoxon paired test and R&R can
be used to evaluate the separability of texture parameters
used to describe textural changes in NHL.
Limitations of our study may be the non-standardized
MRI sequence protocols within intra and inter patient
images and the use of different slice thickness due to
imaging in clinical practice, where patient's clinical stage
and the size of the tumor were taken into account when
setting imaging parameters. However, multicenter studies
on MRI TA have shown transferability of TA parameters
achieved from MRI images obtained at different MRI cent-
ers with own acquisition parameters [16,38].
To achieve new clinical relevant information by means of
texture analysis, the texture changes should come out at
the same or earlier timepoint as other quantitative meas-
ures of tumor response, for example decrease in tumor
volume. The RECIST and WHO criteria for evaluating
tumor response in one- or two-dimensional (diameter
and product) tumor size is equivalent to a 65% decrease
in tumor volume [1]. In this study we calculated tumor
size decrease in a short time period: before and after the
Table 6: Summary table of texture parameters ranked 1-10 with Fisher and POE+ACC methods according to test subgroup T1-
weighted images and imaging timepoints E1 and E3.
T1-WEIGHTED IMAGES R&R R&R Wilcoxon Wilcoxon
E1-E3 analyses Repeatability % of total Reproducibility % of total Slice thickness <8 mm
p
Slice thickness >= 8 mm
p
HISTOGRAM PARAMETERS
MinNorm 24.793 2.445 0.504 0.465
Percentile, 1% 15.349 0.069 0.964 0.715
CO-OCCURENCE MATRIX 
PARAMETERS
Inverse difference moment S(2,0) 20.950 29.298 0.008 0.068
Contrast S(3,0) 27.957 40.317 0.008 0.068
Correlation S(3,0) 24.569 38.395 0.021 0.068
Difference variance S(3,0) 26.169 35.250 0.021 0.068
Contrast S(4,0) 29.032 37.330 0.010 0.068
Correlation S(4,0) 25.661 36.025 0.021 0.068
Inverse difference moment S(4,0) 19.088 34.553 0.004 0.068
Correlation S(4,4) 17.730 40.414 0.021 0.068
Sum of squares S(4,-4) 52.253 2.218 0.859 1.000
Correlation S(5,0) 23.130 39.697 0.016 0.068
Inverse difference moment S(5,0) 23.111 37.188 0.013 0.068
Sum of squares S(0,5) 66.827 1.190 0.041 0.715
Sum of squares S(5,5) 64.191 3.647 0.477 0.715
RUN-LENGTH MATRIX 
PARAMETERS
Grey level nonuniformity, 45° 4.635 13.324 0.003 0.068
Grey level nonuniformity, 135° 4.734 39.630 0.003 0.068
Fraction of image in runs, 135° 13.014 23.544 0.003 0.068
Texture parameters are given in rows. In the columns R&R repeatability and reproducibility of total, and Wilcoxon test for fat saturation series 
grouped with image slice thickness less than 8 mm, and 8 mm or thicker.Journal of Experimental & Clinical Cancer Research 2009, 28:87 http://www.jeccr.com/content/28/1/87
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first cycle of chemotherapy. There are no commonly used
criteria for early response assessment using volumetric
analysis for use as early in the therapy course as our volu-
metric evaluation was performed. Considering this, we
can use the volumetric results as indicative of early imag-
ing based evaluation of response, not to meet response,
and also accept tumor volume decrease percentages
smaller than 65% as consequential decrease in tumor size.
However, in lymphomas, final clinical response evalua-
tion should include other clinical tests according to [5,6].
Wilcoxon test showed encouraging values in the analyses
of E1 and E3, including transferability of feature sets
between T1- and T2-weighted images. This confirms our
recent results with smaller patient data MaZda texture
analysis of combination of T1- and T2-weighted images in
single analysis [32].
Our study show that the statistical and autoregressive
model texture parameters of MRI data can be successfully
tested one by one with Wilcoxon paired test and Gage
Repeatability and Reproducibility test to assess the impact
of parameter separability in evaluating chemotherapy
Table 7: Summary table of texture parameters ranked 1-10 with Fisher and POE+ACC methods according to test subgroup T2-
weighted images and imaging timepoints E1 and E2.
T2-WEIGHTED IMAGES R&R R&R Wilcoxon Wilcoxon
E1-E2 analyses Repeatability % of total Reproducibility % of total Slice thickness <8 mm
p
Slice thickness >= 8 mm
p
HISTOGRAM PARAMETERS
MinNorm 14.090 24.380 0.861 0.636
CO-OCCURENCE MATRIX 
PARAMETERS
Difference variance S(1,-1) 24.802 17.121 0.249 0.266
Sum average S(2,2) 38.483 23.527 0.552 0.163
Contrast S(3,0) 22.618 45.195 0.087 0.025
Contrast S(3,3) 23.282 48.345 0.152 0.102
Contrast S(4,0) 26.599 44.458 0.221 0.013
Contrast S(4,4) 31.083 41.015 0.116 0.049
Difference variance S(4,4) 35.305 32.674 0.196 0.019
Contrast S(4,-4) 40.897 22.850 0.013 0.266
Sum average S(4,-4) 10.802 1.906 0.345 0.210
Contrast S(5,0) 30.110 41.229 0.422 0.007
Sum of squares S(5,0) 64.138 7.335 0.807 0.076
Difference variance S(5,0) 34.811 32.369 0.917 0.009
Contrast S(0,5) 41.519 29.671 0.055 0.210
Contrast S(5,5) 39.461 38.040 0.133 0.102
Sum of squares S(5,5) 80.906 0.000 0.972 0.906
RUN-LENGTH MATRIX 
PARAMETERS
Short run emphasis, 90° 10.659 12.516 0.087 0.149
Fraction of image in runs, 90° 11.662 12.685 0.101 0.124
ABSOLUTE GRADIENT 
PARAMETERS
Mean 18.036 44.271 0.046 0.287
Skewness 63.599 15.598 0.382 0.492
Texture parameters are given in rows. In the columns R&R repeatability and reproducibility of total, and Wilcoxon test for fat saturation series 
grouped with image slice thickness less than 8 mm, and 8 mm or thicker.Journal of Experimental & Clinical Cancer Research 2009, 28:87 http://www.jeccr.com/content/28/1/87
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response in lymphoma tissue. Our results strengthen the
applicability of Fisher and POE+ACC methods used in
MaZda for automatic feature selection, and also confirm
the suitability of the raw parameters in statistical tests.
This indicates that raw parameters may be used in analy-
ses other than LDA, NDA and PCA tests to acquire classi-
fication.
We have shown that texture parameters change during
tumor response to chemotherapy. Comparing initial
imaging to the second imaging timepoint, just after the
first chemotherapy cycle, there were not such clear
changes as at the third imaging timepoint, after four cycles
of chemotherapy. The difference in texture appearance
between staging and the third imaging timepoint was dis-
tinct and emerged from the results of other combinations
in both T1-weighted and T2-weighted image types. There
might have been better separation in texture features
between diagnostic and first evaluation stage if standard-
ized imaging sequence had been used. Our non-standard-
ized MRI sequence may lead too heterogeneous TA
features to exactly describe subtle changes in lymphoma
tissue in extremely early stages of therapy response evalu-
ation. We still cannot state the importance of subtle tex-
tural changes in early response assessment in comparison
to volumetric changes in the same time intervals. Further,
as controls for examined NHL masses no normal lymph
nodes neither NHL masses after treatment were analyzed,
Table 8: Summary table of texture parameters ranked 1-10 with Fisher and POE+ACC methods according to test subgroup T2-
weighted images and imaging timepoints E2 and E3.
T2-WEIGHTED IMAGES R&R R&R Wilcoxon Wilcoxon
E2-E3 analyses Repeatability  % of total Reproducibility % of total Slice thickness <8 mm
p
Slice thickness >= 8 mm
p
HISTOGRAM PARAMETERS
MinNorm 14.090 24.380 0.002 0.124
Variance 1.655 16.743 0.028 0.149
CO-OCCURENCE MATRIX 
PARAMETERS
Contrast S(2,0) 19.563 41.264 0.055 0.001
Contrast S(2,2) 23.139 43.325 0.033 <0,001
Contrast S(3,0) 22.618 45.195 0.023 0.002
Correlation S(3,0) 21.555 40.965 0.009 0.001
Contrast S(0,3) 30.424 34.725 0.116 <0,001
Contrast S(3,3) 23.282 48.345 0.023 0.004
Correlation S(3,3) 22.095 44.779 0.016 0.010
Contrast S(4,0) 26.599 44.458 0.006 0.011
Correlation S(4,0) 23.479 41.166 0.003 0.009
Sum of squares S(4,0) 71.978 3.535 0.807 0.868
Correlation S(4,4) 23.823 42.301 0.016 0.055
Difference entropy S(4,-4) 10.347 7.011 0.039 0.210
Sum average S(0,5) 35.828 0.000 0.972 0.011
Angular second moment S(5,-5) 8.994 12.106 0.064 0.015
Inverse difference moment S(5,-5) 46.459 0.000 0.917 0.795
RUN-LENGTH MATRIX 
PARAMETERS
Grey level nonuniformity, 135° 6.265 33.780 0.003 0.004
ABSOLUTE GRADIENT 
PARAMETERS
Mean 18.036 44.271 0.039 <0,001
Skewness 63.599 15.598 0.221 0.044
Texture parameters are given in rows. In the columns R&R repeatability and reproducibility of total, and Wilcoxon test for fat saturation series 
grouped with image slice thickness less than 8 mm, and 8 mm or thicker.Journal of Experimental & Clinical Cancer Research 2009, 28:87 http://www.jeccr.com/content/28/1/87
Page 12 of 14
(page number not for citation purposes)
since their small size leading to not exact differentiation
from surrounding soft tissue structures in MR images.
The response evaluation of lymphomas under treatment
using radiological imaging methods is connected strongly
with tumor dimensions, instead when using positron
emission tomography, tumor lesion activity of tracer
uptake is measured. Both methods have certain advan-
tages and disadvantages; major disadvantages related to
sensitivity to differentiate residual masses and inflamma-
tory processes from active disease. Functional responses
for nocicepti stimuli and antivascular therapy have been
detected in recent MRI TA studies [18,31]. In this context
changes in textural appearance in MRI during the treat-
ment process probably reflect chemotherapy induced
changes in cellular proliferation.
In treatment with a curative orientation it is essential to
get early an estimate of response to determine further
treatment. MRI texture analysis may provide new insight
to be used alone or in combination with other tools in
diagnostics and response monitoring of non-Hodgkin
lymphomas.
Conclusion
In conclusion NHL tissue MRI texture imaged before treat-
ment and during chemotherapy can be correctly classified.
Our results show promise for texture analysis as a possible
new quantitative means for evaluating NHL response. Sta-
tistical and autoregressive model texture parameters of
MRI data can be successfully tested with Wilcoxon paired
test and Gage Repeatability and Reproducibility test to
assess the impact of the parameters separability in evalu-
ating chemotherapy response in lymphoma tissue.
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Table 9: Summary table of texture parameters ranked 1-10 with Fisher and POE+ACC methods according to test subgroup T2-
weighted images and imaging timepoints E1 and E3.
T2-WEIGHTED IMAGES R&R R&R Wilcoxon Wilcoxon
E1-E3 analyses Repeatability % of total Reproducibility % of total Slice thickness <8 mm
p
Slice thickness >= 8 mm
p
HISTOGRAM PARAMETERS
MinNorm 14.090 24.380 0.003 0.130
CO-OCCURENCE MATRIX 
PARAMETERS
Contrast S(2,0) 19.563 41.264 0.011 0.001
Contrast S(2,2) 23.139 43.325 0.006 <0,001
Contrast S(3,0) 22.618 45.195 0.009 0.001
Correlation S(3,0) 21.555 40.965 0.007 0.001
Sum average S(3,0) 28.935 19.345 0.033 0.035
Contrast S(3,3) 23.282 48.345 0.006 <0,001
Correlation S(3,3) 22.095 44.779 0.007 <0,001
Sum average S(3,-3) 20.384 0.353 0.087 0.017
Contrast S(4,0) 26.599 44.458 0.007 0.001
Contrast S(4,4) 31.083 41.015 0.009 <0,001
Correlation S(4,4) 23.823 42.301 0.007 <0,001
Sum of squares S(4,4) 82.108 0.686 0.345 0.687
Correlation S(5,-5) 39.239 25.122 0.023 0.035
RUN-LENGTH MATRIX 
PARAMETERS
Short run emphasis, 90° 10.659 12.516 0.001 <0,001
Grey level nonuniformity, 45° 15.649 11.529 0.001 <0,001
ABSOLUTE GRADIENT 
PARAMETERS
Mean 18.036 44.271 0.002 0.001
Skewness 63.599 15.598 0.046 0.007
Texture parameters are given in rows. In the columns R&R repeatability and reproducibility of total, and Wilcoxon test for fat saturation series 
grouped with image slice thickness less than 8 mm, and 8 mm or thicker.Journal of Experimental & Clinical Cancer Research 2009, 28:87 http://www.jeccr.com/content/28/1/87
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